Akers Bio logo
Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19
April 06, 2020 09:25 ET | Akers Biosciences Inc.
Successfully obtained clones for all three selected Coronavirus Antigens Thorofare, New Jersey, April 06, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a...
SGI-DNA is now Codex
April 06, 2020 09:07 ET | SGI-DNA
San Diego, April 06, 2020 (GLOBE NEWSWIRE) -- SGI-DNA, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, the BioXp™ 3200 system, today announced the...
emergent logo.jpg
Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
March 31, 2020 16:05 ET | Emergent BioSolutions
CDMO agreement for NanoFlu to support pathway to licensureExpanded collaboration now includes NanoFlu and COVID-19 vaccine candidate GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent...
emergent logo.jpg
Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
January 13, 2020 06:40 ET | Emergent BioSolutions
GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed...
emergent logo.jpg
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
November 22, 2019 08:19 ET | Emergent BioSolutions
GAITHERSBURG, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and...
emergent logo.jpg
Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
October 10, 2019 06:38 ET | Emergent BioSolutions
GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate,...
Batavia Biosciences process development viral vector-based Nipah vaccine
Batavia Biosciences partners with the University of Tokyo to develop a vector-based vaccine against Nipah virus
May 14, 2019 07:00 ET | Batavia Biosciences B.V.
Leiden, the Netherlands, May 14, 2019 – Batavia Biosciences announced today that it will work together in a consortium including the European Vaccine Initiative and Stanford University, icddr,b, and...
emergent logo.jpg
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
March 19, 2019 06:30 ET | Emergent BioSolutions
GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and...
emergent logo.jpg
CEPI vergibt Vertrag im Wert von bis zu 36 Mio. US-Dollar zur Entwicklung eines Impfstoffs gegen das Lassa-Virus an Profectus BioSciences und Emergent BioSolutions
August 16, 2018 06:15 ET | Emergent Biosolutions, Inc.
OSLO, Norwegen, BALTIMORE und GAITHERSBURG, Maryland, USA, Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (die Coalition for Epidemic Preparedness Innovations) gab heute eine neue Kooperation mit Profectus...
emergent logo.jpg
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
August 16, 2018 06:15 ET | Emergent BioSolutions
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus...